Literature DB >> 30903870

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

Lucie Heinzerling1, Paolo A Ascierto2, Reinhard Dummer3, Helen Gogas4, Jean-Jacques Grob5, Celeste Lebbe6, Georgina V Long7, Grant McArthur8, Javid J Moslehi9, Tomas G Neilan10, Antoni Ribas11, Caroline Robert12, Dirk Schadendorf13, Jedd D Wolchok14, Axel Hauschild15.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30903870     DOI： 10.1016/j.ejca.2019.01.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  5 in total

1.  Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System.

Authors:  Emanuel Raschi; Ippazio Cosimo Antonazzo; Michelangelo La Placa; Andrea Ardizzoni; Elisabetta Poluzzi; Fabrizio De Ponti
Journal:  Oncologist       Date:  2019-08-06

Review 2.  Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations.

Authors:  Amalia Anastasopoulou; Dimitrios C Ziogas; Michael Samarkos; John M Kirkwood; Helen Gogas
Journal:  J Immunother Cancer       Date:  2019-09-04       Impact factor: 13.751

3.  Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis.

Authors:  Anne Zaremba; Rafaela Kramer; Viola De Temple; Stefanie Bertram; Martin Salzmann; Anja Gesierich; Lydia Reinhardt; Barouyr Baroudjian; Michael M Sachse; Gunhild Mechtersheimer; Douglas B Johnson; Alison M Weppler; Lavinia Spain; Carmen Loquai; Milena Dudda; Claudia Pföhler; Adriana Hepner; Georgina V Long; Alexander M Menzies; Matteo S Carlino; Céleste Lebbé; Tomohiro Enokida; Makoto Tahara; Paul J Bröckelmann; Thomas Eigentler; Katharina C Kähler; Ralf Gutzmer; Carola Berking; Selma Ugurel; Nadine Stadtler; Antje Sucker; Jürgen C Becker; Elisabeth Livingstone; Friedegund Meier; Jessica C Hassel; Dirk Schadendorf; Maher Hanoun; Lucie Heinzerling; Lisa Zimmer
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

4.  A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma.

Authors:  Elias A T Koch; Niels Schaft; Mirko Kummer; Carola Berking; Gerold Schuler; Kenichiro Hasumi; Jan Dörrie; Beatrice Schuler-Thurner
Journal:  Front Immunol       Date:  2022-02-04       Impact factor: 7.561

Review 5.  Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review.

Authors:  Omar Abdihamid; Abeid Omar; Tibera Rugambwa
Journal:  Ecancermedicalscience       Date:  2021-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.